| 351 | SGHTSight Sciences, Inc. |
77,4 mln USD |
-49,7% |
2025 |
| 352 | BNRBurning Rock Biotech Ltd |
77,2 mln USD |
-10,3% |
2025 |
| 353 | CTMXCytomX Therapeutics, Inc. |
76,2 mln USD |
-22,8% |
2025 |
| 354 | AUTLAutolus Therapeutics plc |
75,4 mln USD |
-381,4% |
2025 |
| 355 | ABCLAbCellera Biologics Inc. |
75,1 mln USD |
-194,9% |
2025 |
| 356 | RXRXRecursion Pharmaceuticals, Inc. |
74,7 mln USD |
-863,4% |
2025 |
| 357 | ELMDElectromed, Inc. |
73,8 mln USD |
15,3% |
2026 |
| 358 | CLLSCellectis S.A. |
72,9 mln USD |
-92,7% |
2025 |
| 359 | CGENCompugen Ltd |
72,8 mln USD |
48,6% |
2025 |
| 360 | BCYCBicycle Therapeutics PLC |
72,6 mln USD |
-301,7% |
2025 |
| 361 | ASMBAssembly Biosciences, Inc. |
72,3 mln USD |
-8,5% |
2025 |
| 362 | RCELAVITA Medical, Inc. |
71,6 mln USD |
-67,8% |
2025 |
| 363 | VRDNViridian Therapeutics, Inc. |
70,8 mln USD |
-483,6% |
2025 |
| 364 | FOCLEdap Tms SA |
70,5 mln USD |
-41,5% |
2025 |
| 365 | BDTXBlack Diamond Therapeutics, Inc. |
70 mln USD |
32,0% |
2025 |
| 366 | PSNLPersonalis, Inc. |
69,6 mln USD |
-116,7% |
2025 |
| 367 | RMTIRockwell Medical, Inc. |
69,3 mln USD |
-7,7% |
2025 |
| 368 | VIRVir Biotechnology, Inc. |
68,6 mln USD |
-638,9% |
2025 |
| 369 | NTLAIntellia Therapeutics, Inc. |
67,7 mln USD |
-609,9% |
2025 |
| 370 | KURAKura Oncology, Inc. |
67,5 mln USD |
-412,9% |
2025 |
| 371 | SPROSpero Therapeutics, Inc. |
66,8 mln USD |
12,8% |
2025 |
| 372 | XGNExagen Inc. |
66,6 mln USD |
-30,0% |
2025 |
| 373 | CCMConcord Medical Services Holdings Ltd |
65,9 mln USD |
-20,2% |
2025 |
| 374 | ENTAEnanta Pharmaceuticals Inc |
65,3 mln USD |
-125,4% |
2025 |
| 375 | COSMCosmos Health Inc. |
65,3 mln USD |
-29,3% |
2025 |
| 376 | FBIOFortress Biotech, Inc. |
63,3 mln USD |
10,8% |
2025 |
| 377 | NUVBNuvation Bio Inc. |
62,9 mln USD |
-325,3% |
2025 |
| 378 | TNGXTango Therapeutics, Inc. |
62,4 mln USD |
-162,9% |
2025 |
| 379 | DERMJourney Medical Corp |
61,9 mln USD |
-18,5% |
2025 |
| 380 | MHUAFMeihua International Medical Technologies Co., Ltd. |
61,8 mln USD |
11,0% |
2025 |
| 381 | TRIBTrinity Biotech PLC |
61,6 mln USD |
-51,6% |
2024 |
| 382 | CSBRChampions Oncology, Inc. |
59,4 mln USD |
-2,0% |
2026 |
| 383 | APTAlpha Pro Tech Ltd |
59,1 mln USD |
6,0% |
2025 |
| 384 | LNSRLENSAR, Inc. |
58,4 mln USD |
-58,7% |
2025 |
| 385 | AYTUAytu Biopharma, Inc |
57,6 mln USD |
-24,8% |
2026 |
| 386 | CVRXCVRx, Inc. |
56,7 mln USD |
-94,1% |
2025 |
| 387 | NKTRNektar Therapeutics |
55,2 mln USD |
-297,1% |
2025 |
| 388 | AGIOAgios Pharmaceuticals, Inc. |
54 mln USD |
-764,0% |
2025 |
| 389 | QTTBQ32 Bio Inc. |
53,7 mln USD |
55,5% |
2025 |
| 390 | IVVDInvivyd, Inc. |
53,4 mln USD |
-98,2% |
2025 |
| 391 | APYXApyx Medical Corp |
52,8 mln USD |
-21,2% |
2025 |
| 392 | PLXProtalix BioTherapeutics, Inc. |
52,7 mln USD |
-12,5% |
2025 |
| 393 | IRIXIridex Corp |
52,7 mln USD |
-8,4% |
2026 |
| 394 | OCULOcular Therapeutix, Inc |
52 mln USD |
-511,9% |
2025 |
| 395 | CARLCarlsmed, Inc. |
50,5 mln USD |
-58,7% |
2025 |
| 396 | LXRXLexicon Pharmaceuticals, Inc. |
49,8 mln USD |
-101,1% |
2025 |
| 397 | GOSSGossamer Bio, Inc. |
48,5 mln USD |
-351,5% |
2025 |
| 398 | SIShoulder Innovations, Inc. |
47,3 mln USD |
-85,3% |
2025 |
| 399 | CAPSCapstone Holding Corp. |
46,9 mln USD |
-45,3% |
2025 |
| 400 | PTGXProtagonist Therapeutics, Inc |
46 mln USD |
-282,8% |
2025 |